Skip to main content
Medical information Clinical review pending

Genetic Testing

KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the KCNC1 gene for mutations associated with Progressive Myoclonic Epilepsy Type 7. Helps in diagnosing and managing this neurological condition.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree chart.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Progressive Myoclonic Epilepsy Type 7
  • ✓Presence of myoclonic seizures
  • ✓Progressive neurological decline
  • ✓Family history of PME or KCNC1 mutations
  • ✓Genetic counseling for families with PME
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the KCNC1 gene associated with Progressive Myoclonic Epilepsy Type 7, aiding in diagnosis and informing management strategies.
The KCNC1 Gene Epilepsy Progressive Myoclonic Type 7 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to progressive myoclonic epilepsy (PME). PME is a group of rare, inherited neurological disorders characterized by myoclonic seizures, progressive neurological decline, and often, other symptoms. Early and accurate diagnosis is important for managing the condition effectively.

This test utilizes Next-Generation Sequencing (NGS) technology to examine the KCNC1 gene. Variations in this gene can cause PME Type 7. Identifying these specific genetic changes provides crucial information for healthcare providers to understand the cause of the condition and guide treatment strategies.

This test is recommended for individuals showing signs of PME or those with a family history of the condition. Understanding the genetic basis of the epilepsy can help in planning appropriate medical care, genetic counseling, and family planning.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree chart.
SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the KCNC1 gene for relevant mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes the KCNC1 gene specifically. It may not detect mutations in other genes associated with PME or other epilepsy types. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

It is a rare, inherited neurological disorder characterized by myoclonic seizures and progressive neurological decline, caused by mutations in the KCNC1 gene.
Individuals with symptoms like myoclonic seizures, progressive neurological decline, or a family history of PME or KCNC1 mutations should discuss this test with their doctor.
The test analyzes a sample of your blood or DNA using Next-Generation Sequencing (NGS) to look for specific changes in the KCNC1 gene.
Results indicate the presence or absence of specific KCNC1 gene mutations. A genetic counseling session is recommended to understand the implications of the results.
Yes, a detailed clinical history of the patient is necessary for proper test interpretation. A genetic counseling session is also recommended.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp